natgillin/translations-raw huggingface dataset:
The CHMP decided that Irbesartan Hydrochlorothiazide Zentiva’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et ravimi Irbesartan Hydrochlorothiazide Zentiva kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Irbesartan Zentiva’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Irbesartan Zentiva kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Iscover’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Iscoveri kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Isentress’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Isentressi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Ivemend’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Ivemendi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda müügiloa.
The CHMP decided that Ixiaro’s benefits are greater than its risks and noted that the production of the only other vaccine for protection against Japanese encephalitis that was in use outside Asia had been discontinued.
Inimravimite komitee otsustas, et Ixiaro kasulikkus on suurem kui sellega kaasnevad riskid, ning märkis, et ainsa muu väljaspool Aasiat kasutatava Jaapani entsefaliidi vastase vaktsiini tootmine on lõppenud.
The CHMP decided that Jakavi’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Jakavi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Januvia’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee järeldas, et Januvia kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Javlor’s benefits are greater than its risks and recommended that Javlor be given marketing authorisation.
Inimravimite komitee otsustas, et Javlori kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Kaletra’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Kaletra kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Karvea’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Karvea kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Karvezide’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Karvezide kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Kepivance’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Kepivance’i ei soovitata kasutada lastel (0–18 a)
The CHMP decided that Keppra’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Keppra kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Kineret’s benefits are greater than its risks for the treatment of the signs and symptoms of rheumatoid arthritis in combination with methotrexate, in patients with an inadequate response to methotrexate alone.
Inimravimite komitee otsustas, et Kinereti kasulikkus reumatoidartriidi nähtude ja sümptomite ravis koos metotreksaadiga patsientidel, kellel ei teki üksnes metotreksaadi kasutamisel adekvaatset ravivastust, on suurem kui sellega kaasnevad riskid.
The CHMP decided that Kinzalkomb’s benefits are greater than its risks for the treatment of essential hypertension in patients whose blood pressure is not adequately controlled on telmisartan alone.
Inimravimite komitee otsustas, et Kinzalkombi kasulikkus nende essentsiaalse hüpertensiooniga patsientide ravis, kelle vererõhku ei saa ainult telmisartaaniga piisavalt reguleerida, on suurem kui ravimiga kaasnevad riskid.
The CHMP decided that Kinzalmono’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Kinzalmono kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Kivexa’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Kivexa kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Kogenate Bayer’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Kogenate Bayeri kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda müügiloa.
The CHMP decided that Kuvan’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Kuvani kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Lantus’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Lantuse kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Leflunomide Winthrop’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Leflunomide Winthropi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Leganto’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Leganto kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Levemir’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Levemiri kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Levitra’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Levitra kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Levodopa/Carbidopa/Entacapone Orion’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et ravimi Levodopa/Carbidopa/Entacapone Orion kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Livensa’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Livensa kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Lucentis’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Lucentise kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda müügiloa.
The CHMP decided that Luminity’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Luminity kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Luveris’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Luverise kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda müügiloa.
The CHMP decided that Lyrica’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Lyrica kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda müügiloa.
The CHMP decided that Lysodren’s benefits are greater than its risks for the treatment of advanced adrenal cortical carcinoma, but noted that the effect of Lysodren has not been established in adrenal cortical carcinoma that is not producing high levels of steroid hormones.
Inimravimite komitee otsustas, et Lysodreni kasulikkus neerupealise koore kaugelearenenud vähi ravis on suurem kui sellega seotud riskid, kuid märkis, et Lysodreni toimet ei ole kindlaks määratud neerupealise koore sellise vähi korral, mis ei põhjusta steroidhormoonide sisalduse suurenemist veres.
The CHMP decided that M-M-RVAXPRO’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et M-M-RVAXPRO kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda vaktsiini müügiloa.
The CHMP decided that Macugen’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Macugeni kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Memantine Merz’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et ravimi Memantine Merz kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Mepact’s benefits are greater than its risks when used with other anticancer medicines and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et kasutamisel koos muude vähiravimitega on Mepacti kasulikkus suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Micardis’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Micardise kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Mirapexin’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Mirapexini kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Mixtard’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee järeldas, et Mixtardi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Modigraf’s benefits are greater than its risks for prophylaxis of transplant rejection in kidney, liver and heart recipients, and in the treatment of rejection resistant to treatment with other immunosuppressive medicinal products.
Inimravimite komitee otsustas, et Modigrafi kasulikkus on suurem kui sellega kaasnevad riskid elundi äratõukereaktsiooni ennetamiseks neeru-, maksa- või südamesiirdepatsientidel ning äratõukereakstiooni raviks patsientidel, kellel ei teki ravivastust teistele immunosupressantidele.
The CHMP decided that Myozyme’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Myozyme kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Naglazyme’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Naglazyme kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Neoclarityn’s benefits are greater than its risks for the relief of symptoms associated with allergic rhinitis or urticaria and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Neoclarityni kasulikkus allergilise riniidi või urtikaaria sümptomite leevendamisel on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that NeoRecormon’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et NeoRecormoni kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Neulasta’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Neulasta kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Neupro’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Neupro kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that NeuroBloc’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et NeuroBloci kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Nevanac’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Nevanaci kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Nexavar’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Nexavari kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that NexoBrid’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et NexoBridi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Nonafact’s benefits are greater than its risks for the treatment and prevention of bleeding in patients with haemophilia B. They recommended that Nonafact be given marketing authorisation.
Inimravimite komitee otsustas, et Nonafacti kasulikkus B-hemofiiliaga patsientidel verejooksude ravis ja ennetamisel on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Norvir’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Norviri kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that NovoMix’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et NovoMixi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda müügiloa.
The CHMP decided that NovoSeven’s benefits are greater than its risks for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in patients with congenital haemophilia, acquired haemophilia, congenital factor VII deficiency or Glanzmann’s thrombasthenia.
Inimravimite komitee otsustas, et kaasasündinud hemofiilia, omandatud hemofiilia, VII hüübimisteguri vaeguse või Glantzmanni trombasteeniaga patsientide verejooksude ravis ja ennetamisel operatsiooni või invasiivsete protseduuride korral on NovoSeveni kasulikkus suurem kui sellega kaasnevad riskid.
The CHMP decided that Nplate’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Nplate kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Onbrez Breezhaler’s benefits are greater than its risks and recommended that Onbrez Breezhaler be given marketing authorisation.
Inimravimite komitee otsustas, et Onbrez Breezhaleri kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Onsenal’s benefits are greater than its risks but noted that no effect of Onsenal on the risk of developing cancer of the intestine had been shown.
Inimravimite komitee otsustas, et Onsenali kasulikkus on suurem kui sellega kaasnevad riskid, kuid märkis, et ei ole leitud tõendeid selle kohta, et Onsenali ravi mõjutaks soolevähi tekkimise riski.
The CHMP decided that Opatanol’s benefits are greater than its risks for the treatment of ocular signs and symptoms of seasonal allergic conjunctivitis and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Opatanoli kasulikkus hooajalise allergilise konjunktiviidi silmasümptomite ja -nähtude ravis on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Opgenra’s benefits are greater than its risks for posterolateral lumbar spinal fusion in adult patients with spondylolisthesis where autograft has failed or is contra-indicated.
Inimravimite komitee otsustas, et Opgenra kasulikkus spondülolisteesiga täiskasvanud patsientide lülisamba nimmeosa lülide posterolateraalsel ühendamisel, kui autoloogse luuimplantaadi kasutamine on ebaõnnestunud või vastunäidustatud, on suurem kui sellega kaasnevad riskid.
The CHMP decided that Optimark’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Optimarki kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda müügiloa.
The CHMP decided that Orgalutran’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Orgalutrani kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Osigraft’s benefits are greater than its risks and recommended that Osigraft be given marketing authorisation.
Inimravimite komitee otsustas, et Osigrafti kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Oslif Breezhaler’s benefits are greater than its risks and recommended that Oslif Breezhaler be given marketing authorisation.
Inimravimite komitee otsustas, et Oslif Breezhaleri kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Osseor’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Osseori kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Ovitrelle’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Ovitrelle kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Pandemic Influenza Vaccine H5N1 Baxter AG’s benefits are greater than its risks in all age groups investigated and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et vaktsiini Pandemic Influenza Vaccine H5N1 Baxter AG kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda vaktsiini müügiloa.
The CHMP decided that Pandemrix’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Pandemrixi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda vaktsiini müügiloa.
The CHMP decided that Panretin’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Panretini kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Pedea’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Pedea kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda vaktsiini müügiloa.
The CHMP decided that Pegasys’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Pegasysi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that PegIntron’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et PegIntroni kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Pergoveris’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Pergoverise kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda müügiloa.
The CHMP decided that Peyona’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Peyona kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that PhotoBarr’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et PhotoBarri kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Plavix’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Plavixi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Possia’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Possia kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Pregabalin Pfizer’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Pregabalin Pfizeri kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Preotact’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Preotacti kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et vaktsiini Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda vaktsiini müügiloa.
The CHMP decided that Prepandrix’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Prepandrixi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda vaktsiini müügiloa.
The CHMP decided that Prevenar 13’s benefits are greater than its risks and recommended that it be granted marketing authorisation.
Inimravimite komitee otsustas, et vaktsiini Prevenar 13 kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda vaktsiini müügiloa.
The CHMP decided that Prevenar’s benefits are greater than its risks and recommended that Prevenar be given marketing authorisation.
Inimravimite komitee otsustas, et Prevenari kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Prezista’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Prezista kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.